S
SRPT icon

SignatureFD’s Sarepta Therapeutics SRPT Stock Holding History

SignatureFD’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5K Buy
583
+115
+25% +$2.17K ﹤0.01% 2619
2026
Q1 		$10.2K Sell
468
-386
-45% -$7.47K ﹤0.01% 2505
2025
Q4 		$18.4K Buy
854
+474
+125% +$9.99K ﹤0.01% 2159
2025
Q3 		$7.32K Sell
380
-604
-61% -$10.8K ﹤0.01% 2517
2025
Q2 		$16.8K Buy
984
+208
+27% +$8.87K ﹤0.01% 2134
2025
Q1 		$49.5K Buy
776
+86
+12% +$9.05K ﹤0.01% 1573
2024
Q4 		$83.9K Sell
690
-7,417
-91% -$909K ﹤0.01% 1324
2024
Q3 		$1.01M Sell
8,107
-2,644
-25% -$366K 0.02% 333
2024
Q2 		$1.7M Buy
10,751
+9,942
+1,229% +$1.28M 0.03% 188
2024
Q1 		$105K Buy
809
+262
+48% +$32.1K ﹤0.01% 1154
2023
Q4 		$52.7K Sell
547
-36
-6% -$3.45K ﹤0.01% 1429
2023
Q3 		$70.7K Buy
583
+101
+21% +$11.4K ﹤0.01% 1225
2023
Q2 		$55.2K Buy
482
+41
+9% +$5.29K ﹤0.01% 1367
2023
Q1 		$60.8K Buy
441
+57
+15% +$7.39K ﹤0.01% 1287
2022
Q4 		$49.8K Buy
384
+8
+2% +$927 ﹤0.01% 1372
2022
Q3 		$42K Buy
376
+7
+2% +$706 ﹤0.01% 1367
2022
Q2 		$28K Sell
369
-4
-1% -$294 ﹤0.01% 1611
2022
Q1 		$29K Sell
373
-308
-45% -$23.6K ﹤0.01% 1657
2021
Q4 		$61K Sell
681
-64
-9% -$5.47K ﹤0.01% 1248
2021
Q3 		$69K Buy
745
+82
+12% +$6.32K ﹤0.01% 1144
2021
Q2 		$52K Buy
663
+383
+137% +$29K ﹤0.01% 1253
2021
Q1 		$21K Buy
280
+237
+551% +$21.9K ﹤0.01% 1559
2020
Q4 		$7K Buy
43
+4
+10% +$593 ﹤0.01% 1856
2020
Q3 		$5K Buy
39
+11
+39% +$1.67K ﹤0.01% 1920
2020
Q2 		$4K Buy
28
+20
+250% +$2.72K ﹤0.01% 1909
2020
Q1 		$1K Buy
8
+1
+14% +$114 ﹤0.01% 2195
2019
Q4 		$1K Hold
7
– – ﹤0.01% 2108
2019
Q3 		$1K Buy
7
+6
+600% +$709 ﹤0.01% 2013
2019
Q2 		$0 Buy
+1
New +$122 ﹤0.01% 2152

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

SignatureFD's SRPT Position: Q2 2026 in Review

SignatureFD increased its Sarepta Therapeutics (SRPT) stake by 25% in Q2 2026, buying an estimated $2.17K and bringing the position to 583 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2619.

SignatureFD first reported a position in SRPT in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.7M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • SignatureFD held 583 shares of Sarepta Therapeutics worth $10.5K as of Q2 2026.
  • SignatureFD bought 115 Sarepta Therapeutics shares in Q2 2026, an estimated $2.17K.
  • Sarepta Therapeutics made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2619 holding.
  • SignatureFD first reported a position in Sarepta Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • SignatureFD's Sarepta Therapeutics position peaked at $1.7M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.